ReviewCurrent medicinal chemistry2025
Natural Anticancer Drugs: Efficacy, Safety, and Future Challenges.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Quinoline-Based Scaffolds in Anticancer Drug Discovery: Molecular Targets, Synthetic Strategies, and Biological Advances.ChemMedChem · 2026Review
- Camptothecin Nanoformulations: Recent Advances in Preparation, Bioactivities, and Clinical Perspectives.Annals of biomedical engineering · 2026Review
- From Marine Peptides to Oncology: The Therapeutic Potential of Conotoxins in Cancer Treatment.Chemistry & biodiversity · 2026Review
- Pharmacological Mechanisms of Ursolic Acid Derivative Against Prostate Cancer via Regulating Cytoskeletal Homeostasis and Apoptotic Pathways.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Gene regulatory and biomolecular networks and their multifaceted biotechnological applications.World journal of microbiology & biotechnology · 2026Review
- Natural Medicines Modulating Tumor Perineural Invasion: Regulatory Mechanisms and Therapeutic Potential.Drug design, development and therapy · 2026Review
- Computational screening of natural phenolic compounds as potential EGFR inhibitors against triple negative breast cancer.Journal of molecular modeling · 2025Article
- Investigating the in-vitro and in-vivo potential of Eudrilus eugeniae coelomic fluid fractions on cancer cell lines: insights into mechanisms and therapeutic implications.Medical oncology (Northwood, London, England) · 2025Article
- Exploring the therapeutic role of Moringa oleifera in neurodegeneration: antioxidant, anti-inflammatory, and neuroprotective mechanisms.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The investigation of naturally derived anticancer drugs has gained prominence in cancer therapy research. Within a broad context, this review seeks to elucidate the molecular foundations and diverse mechanisms underlying these compounds to understand their pivotal role in advancing effective interventions. Additionally by employing a systematic approach, this study examined the interplay between cellular components, signaling pathways, and genetic factors, providing valuable insights into the regulatory networks governing the efficacy of these drugs. Categorization based on sources (plants, animals, marine organisms, and microbes) revealed unique bioactive constituents and therapeutic potential. Mechanistic investigations have revealed the ability of these compounds to induce apoptosis, inhibit angiogenesis, modulate metabolic processes, stimulate the immune system, and arrest the cell cycle. This overview encompasses both approved drugs and those undergoing clinical trials, highlighting their heightened efficacy and reduced toxicity compared to their synthetic counterparts. However, challenges persist in terms of standardization, quality control, and large-scale production. In conclusion, this review examined the potential of naturally derived anticancer drugs to contribute to advancements in cancer treatment and enhance patient outcomes. In addition to their effectiveness, natural anticancer drugs are generally less toxic and have fewer harmful side effects than conventional chemotherapies. This emphasizes the need for continued research, collaborative efforts, and addressing the regulatory and intellectual property challenges associated with natural products. This review provides a balanced perspective on the mechanisms, advantages, and prospects.
Indexed as
Identifiers
39871571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.